Sobi is the global supplier of the drug substance for ReFacto AF®/XYNTHA®, a drug sold by Pfizer for the treatment of hemophilia A. Manufacturing takes place in the GMP biologics facility in Stockholm.
Sobi also receives royalty on Pfizer’s global sales of ReFacto.
In February 2012, the manufacturing agreement with Pfizer was extended to 2020, with an option to be further prolonged.
The total revenues for ReFacto (manufacturing and royalty revenues) in 2012 was MSEK 565.8.